First-line ribociclib and endocrine therapy may be more effective than combined chemotherapy in aggressive breast cancer

In patients with hormone receptor-positive, HER2-negative, advanced breast cancer—including patients with visceral crises—those treated with ribociclib plus endocrine therapy had fewer adverse events and a significantly longer progression-free survival compared to those treated with combination chemotherapy, according to results from the phase II RIGHT Choice trial presented at the 2022 San Antonio Breast Cancer Symposium, held December 6-10, 2022. Visceral crisis is defined as the presence of metastases that compromise the function of vital organs.